A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COMET-1
  • Sponsors Exelixis
  • Most Recent Events

    • 06 Jun 2017 Results assessing a week 13 Circulating tumor cell prostate-specific antigen (PSA) endpoint relative to baseline in 5 prospective randomized phase 3 registration trials (n=5912, COU-AA-301, AFFIRM, ELM-PC-5, ELM-PC-4 and COMET-1 trials) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Jul 2016 Results published in the Journal of Clinical Oncology (2016).
    • 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top